[5] [6] The guideline emphasises a stepwise approach to treatment intensification, typically progressing from metformin monotherapy to dual therapy (often with an SGLT2 inhibitor, DPP-4 inhibitor, pioglitazone, or sulphonylurea), and then to triple therapy or insulin-based regimens
(This doesnt mean everyone gets these benefits equally, and it doesnt replace individualized medical screeningbut it reinforces the metabolic health framing.) 6) Neuroprotective potential (emergingstill not an approved use) You may have seen headlines about GLP-1s and brain health
Nassar M, Abosheaishaa H, Misra A, et al
These approaches included anti-IGF-1R monoclonal antibodies (mAbs), IGF-1R tyrosine kinase inhibitors (TKIs), IGF-1/2 blocking mAbs, IGF ligand-TRAPs, recombinant IGFBPs and pregnancy-associated plasma protein-A (PAPP-A) inhibition [54,55]
Thomas Garvey, a former FDA official and drug industry consultant who has testified against McNeil in trials, called the amount of time the FDA had taken to reach a final ruling remarkable and unusual. There are still many questions about this drug, Garvey said
NAD+ is also involved in energy production, so supplementation may boost energy levels and reduce fatigue
